Hi mama — Dr. Ana-Maria here.
If your child has eczema, you already know this isn’t “just dry skin.”
It’s the 2 a.m. scratching. The bleeding cheeks. The tears at bath time. The constant second-guessing: Is it the eggs? The detergent? The dog? Why does nothing seem to stick?
Most families end up playing eczema whack-a-mole — jumping from one cream to the next, one elimination diet to another, searching desperately for something that actually works.
And then, at some point, your provider may say: “We’ve tried topical steroids. It’s time to consider Dupixent.”
Here’s what I want you to know: Dupixent can help some children. But for most families, starting with a comprehensive root-cause approach is the better first step.
Why? Because Dupixent is designed to suppress symptoms by blocking immune signaling. Our program is designed to change why your child keeps flaring in the first place.
That difference matters — for your child’s health, your peace of mind, and yes, your long-term finances too.
The Quick Version (For Busy Parents) TLDR
- FDA-approved injection for moderate-to-severe eczema (6 months+)
- Trial results: 28% clear/almost-clear at 16 weeks
- Side effects: Injection site reactions, conjunctivitis (5%), herpes simplex infections
- Emerging: Association with cutaneous T-cell lymphoma (CTCL) – ~4x higher risk
- Cost: ~$4,193 per 4-week supply (wholesale)
- Retrospective study of 197 children (Avg age 3.41)
- 89% success rate (significant improvement) at 6 months
- 56.2% average reduction in severity scores
- Greatest improvements seen in most severe baseline cases
- Addresses: Nutrition, gut health, toxins, stress, and microbiome
Why the Medical System Steers Toward Medications First
You’ll hear this a lot: “Dupixent has randomized controlled trials. Lifestyle programs don’t.” That’s true — but it’s not the whole story.
Here’s the reality: Modern medicine is built around drug approval pathways. Randomized controlled trials (RCTs) are expensive, and pharmaceutical companies fund them because they need FDA approval to sell their products. The Dupixent trials in young children were funded by Sanofi and Regeneron — the companies that manufacture and profit from the drug.
That doesn’t mean the science is invalid. It means:
- The system naturally produces more drug evidence than lifestyle evidence — because that’s where the money flows.
- Lifestyle and root-cause programs are different. They can’t be standardized into a single pill. They involve behavior change, dietary adjustments, home environment modifications, and ongoing support. They rarely have pharmaceutical companies funding large-scale trials.
But that doesn’t mean they don’t work. It means we have to look at different kinds of evidence — and we did exactly that.
What Dupixent Does — And What It Doesn’t
Dupixent (dupilumab) is a monoclonal antibody that blocks interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling — two immune pathways heavily involved in eczema inflammation. It’s indicated for patients 6 months and older with moderate-to-severe atopic dermatitis that isn’t adequately controlled with topical treatments.
The trial results look impressive. In the pivotal LIBERTY AD PRESCHOOL trial (ages 6mo–5yrs):
- 28% achieved clear or almost-clear skin at 16 weeks (vs. 4% on placebo)
- 53% achieved 75% or greater improvement (vs. 11% on placebo)
- 70% average improvement in EASI scores (vs. 20% on placebo)
Side Effects Are Real
According to FDA prescribing information and clinical trial data, common adverse reactions include: Injection site reactions, conjunctivitis and keratitis (occurred in 5% on Dupixent vs 0% on placebo), Oral herpes, Blepharitis, Dry eye, and Hypersensitivity reactions (anaphylaxis).
Emerging Safety Concerns
Recent research has raised questions about a potential link between Dupixent and cutaneous T-cell lymphoma (CTCL). A 2024 study in the Journal of the American Academy of Dermatology found patients had approximately 4 times higher odds of developing CTCL. The FDA has placed Dupixent on its watch list for potential regulatory action. While absolute risk remains low, the drug may mask or delay diagnosis of existing lymphomas.
The Fundamental Limitation
Dupixent can calm the fire — but it doesn’t teach you how to stop starting it. It blocks immune signaling; it doesn’t address why the immune system is overreacting. For many, that means staying on medication indefinitely without long-term data on decades of use starting in infancy.
What Our Program Does Differently
The Eczema Transformation Program is built around one guiding principle: Eczema improves when you change the inputs. Not just the creams. Not just the symptoms. The actual drivers of inflammation.
Our Research Findings (May 2024 – May 2025)
Retrospective observational study of 197 children (Mean baseline PO-SCORAD 51.4 – Severe Range):
In simple terms: 9 out of 10 families who complete our program see significant improvement.
What the Program Includes
Our 6-month online program addresses the multifactorial nature of eczema through five core pillars:
A Fair Comparison: Different Questions, Different Answers
| Metric | Dupixent Trial (RCT) | Our Observational Study |
|---|---|---|
| Question Asked | Does this drug reduce symptoms vs placebo? | Can families change drivers in daily life? |
| Validity | Strong internal validity (Randomized) | Real-world families, real-home challenges |
| Duration | 16-week snapshot | Meaningful data over 6 months |
| Medications | Participants also used topical steroids | Emphasis on lifestyle; many tapered steroids |
The True Cost of Each Approach
The Financial Reality of Dupixent
Wholesale cost is ~$4,193 per 4-week supply—roughly $50,000 annually. While insurance helps, families face prior authorizations, “step therapy” hurdles, and the risk of losing coverage. This is a long-term financial commitment.
The Hidden Costs Beyond Dollars
Time for injections, stress of managing refills, and the uncertainty of wondering how long your child will need the medication.
The Investment in Root-Cause Healing
Our program requires time and effort to learn new habits and patience as change takes weeks. But the skills you build become yours forever. You learn your child’s triggers and build routines that prevent flares.
A Word About Guilt — Please Read This
I know some of you reading this are already giving your child Dupixent. Please hear me: You are not failing your child.
If Dupixent is keeping your child’s skin from cracking, helping them sleep, and allowing them to go to school — that is a good thing. That is relief. There is no shame in using Dupixent.
What we want you to understand is this: Dupixent doesn’t have to be your only strategy, and it doesn’t have to be forever. Many families use medication to stabilize symptoms while simultaneously working on root-cause changes, eventually tapering under medical supervision.
Ready to Take the Next Step?
If you’re tired of living in fear of the next flare… if you want a plan that focuses on why eczema is happening — not just what to put on it…
Frequently Asked Questions
Is Dupixent dangerous?
Every medication carries risks. Dupixent has known warnings including hypersensitivity reactions, eye inflammation (conjunctivitis and keratitis), injection site reactions, and herpes viral infections. Recent studies have also identified an association with cutaneous T-cell lymphoma, though this remains under investigation. Discuss the risk-benefit profile with your child’s doctor.
Does Dupixent cure eczema?
No. Dupixent reduces symptoms by blocking immune signaling. It does not address underlying triggers or teach root-cause strategies. Symptoms often return if the medication is stopped.
How fast can your program help?
In our outcomes evaluation, families saw an average improvement of 11.3 points on the PO-SCORAD by 1 month — already exceeding the clinically meaningful threshold. By 6 months, improvement averaged 31.2 points (56% reduction in severity). Looking at success rates: 54% of children showed significant improvement at just 1 month, growing to 89% by 6 months. That means 9 out of 10 families who complete the program see meaningful results.
Is your program evidence-based?
We have completed research that has been submitted for publication in a peer-reviewed journal. Our outcomes evaluation uses a validated assessment tool (PO-SCORAD) and shows clinically meaningful, statistically significant improvements. We’re transparent about the limitations of observational data and encourage further controlled studies.
What if my child’s eczema is severe?
Our research included many children with severe symptoms at baseline — and this group actually showed the greatest improvements. Severe cases require expert management, and our program was designed to support families who feel like they’ve tried everything.
Can we do your program while our child is on Dupixent?
Absolutely. Many families begin our program while using Dupixent or other medications. Root-cause work can complement medical treatment, and over time, some families are able to reduce their medication use under their doctor’s supervision.
Dr. Ana-Maria Temple, MD, is the founder of Integrative Health Carolinas and creator of the Eczema Transformation Program. This article is for educational purposes and does not constitute medical advice. Always consult your child’s healthcare provider before making changes to their treatment plan.
